We analysed the expression profiles of 70 kidney tumors of different histological subtypes to determine if these subgroups can be distinguished by their gene expression profiles, and to gain insights into the molecular mechanisms underlying each subtype. In all, 39 clear cell renal cell carcinomas (RCC), seven primary and one metastatic papillary RCC, six granular RCC from old classification, five chromophobe RCC, five sarcomatoid RCC, two oncocytomas, three transitional cell carcinomas (TCC) of the renal pelvis and five Wilms' tumors were compared with noncancerous kidney tissues using microarrays containing 19 968 cDNAs. Based on global gene clustering of 3560 selected cDNAs, we found distinct molecular signatures in clear cell, papillary, chromophobe RCC/ oncocytoma, TCC and Wilms' subtypes. The close clustering in each of these subtypes points to different tumorigenic pathways as reflected by their histological characteristics. In the clear cell RCC clustering, two subgroups emerged that correlated with clinical outcomes, confirming the potential use of gene expression signatures as a predictor of survival. In the so-called granular cell RCC (terminology for a subtype that is no longer preferred), none of the six cases clusters together, supporting the current view that they do not represent a single entity. Blinded histological re-evaluation of four cases of 'granular RCC' led to their reassignment to other existing histological subtypes, each compatible with our molecular classification. Finally, we found gene sets specific to each subtype. In order to establish the use of some of these genes as novel subtype markers, we selected four genes and performed immunohistochemical analysis on 40 cases of primary kidney tumors. The results were consistent with the gene expression microarray data: glutathione S-transferase a was highly expressed in clear cell RCC, a methylacyl racemase in papillary RCC, carbonic anhydrase II in chromophobe RCC and K19 in TCC. In conclusion, we demonstrated that molecular profiles of kidney cancers closely correlated with their histological subtypes. We have also identified in these subtypes differentially expressed genes that could have important diagnostic and therapeutic implications.
Introduction
Renal cell carcinoma (RCC) is the most common malignancy of the adult kidney, representing 2% of all malignancies and 2% of cancer-related deaths. The incidence of RCC is increasing, a trend that cannot be explained by the increased use of abdominal imaging procedures alone (Chow et al., 1999) .
RCC is a clinicopathologically heterogeneous disease subdivided into clear cell, papillary, chromophobe, collecting duct and unclassified (WHO International Histological Classification of Kidney Tumors; Mostfi and Davis, 1998) . Clear cell RCC is the most common adult renal neoplasm representing 70% of all renal neoplasms, and is thought to originate in the proximal tubules. Papillary RCC accounts for 10-15%, chromophobe RCC 4-6%, collecting duct carcinoma o1% and unclassified lesions 4-5% of RCC. Some of these tumors show sarcomatoid change (sometimes called spindle RCC or sarcomatoid RCC) and are thought to represent the high-grade end of all subgroups. Finally, the granular cell RCC, an old term that is no longer included in the current classification systems, is still being diagnosed by many pathologists around the world. Instead, granular RCC can often be reclassified into other subtypes (Storkel et al., 1997) .
With recent advances in molecular genetics, the subtypes of RCC have been associated with distinct genetic abnormalities. This association has led to a proposal for molecular diagnosis of RCC (Bugert and Kovacs, 1996) . The majority of clear cell RCC, for example, has a loss of chromosome 3 and inactivating mutations of the VHL gene, whereas papillary RCC are frequently associated with trisomy of chromosomes 3q, 7, 12, 16, 17 and 20 , and loss of the Y chromosome. A portion of them also harbor MET mutations. It has been proposed that, even in the absence of prominent papillae, these aberrant chromosomal features could support the diagnosis of papillary RCC. Conversely, kidney cancers that do not possess these genetic characteristics should not be designated as papillary RCC even when papillary structures are prominent (Storkel et al., 1997) . Frequent loss of sex chromosomes, chromosomes 1 and 14 have been found in renal oncocytoma, a benign tumor composed of large eosinophilic cells arranged in acini (Presti et al., 1996) . Accurate subtyping of renal tumors is critical for predicting prognosis and designing appropriate treatment for patients (Motzer et al., 2002) .
To date, microarray technology has provided comprehensive insights into the underlying molecular mechanisms of many types of cancers. These gene expression profiles can serve as the molecular signatures of cancer, and may be used to distinguish among histological subtypes as well as to aid in the discovery of novel clinical subtypes such as those related to drug response. These distinctions may reflect the heterogeneity in transformation mechanisms, cell types, and behavior of the tumors. For example, several studies have identified distinct gene sets that distinguish serous and mucinous ovarian cancer (Ono et al., 2000) , acute myeloid and acute lymphoblastic leukemias (Golub et al., 1999) , BRCA1 and BRCA2 hereditary breast cancer (Hedenfalk et al., 2001) , hepatitis-B and hepatitis-C hepatocellular carcinomas (Okabe et al., 2001) and diffuse large B-cell lymphomas with good and poor prognosis (Rosenwald et al., 2002) .
In kidney tumors, distinctive molecular signatures for clear cell RCC and chromophobe RCC/oncocytoma were previously shown (Boer et al., 2001; Young et al., 2001) . More recently, we identified a prognostic gene set in clear cell RCC that could distinguish between patients with good or poor outcome (Takahashi et al., 2001) . Obviously, there is a need to extend the profiling to include other subtypes of kidney tumors.
In this study, we examined the molecular signatures of 70 kidney tumors from seven different subgroups: clear cell, papillary, granular, chromophobe, sarcomatoid RCC, oncocytoma, transitional cell carcinoma (TCC) of the renal pelvis and pediatric Wilms' tumors by using cDNA microarray analysis. Our aims were twofolds. First, we intended to establish a molecular subclassification based on expression profiles. We then tested its potential use by including six cases of 'granular cell RCC' which were diagnosed prior to the recommendation by the work group of UICC (Union Internationale Contre le Cancer) and AJCC (American Joint Committee on Cancer) (Storkel et al., 1997) . This is to determine if their recommendation was supported by gene expression-based molecular subclassification. Our second aim was to identify novel genes that may serve as novel diagnostic markers. The strength of the candidacy as new diagnostic markers lay in the number of subtypes included in the studies. Using statistical method, we could select the genes that were unique to one subgroup and thus were able to distinguish against other subgroups. We then established their potential use in diagnosis by performing immunohistochemical staining on paraffin-embedded blocks of primary kidney tumors using antibodies of four selected genes which have corresponding monoclonal antibody available.
Results
We used hierarchical clustering (Eisen et al., 1998) to classify kidney tumors based on their gene expression profiles using the expression ratios of a selected 3560 cDNA set (see Materials and methods). The clustering algorithm groups both genes and tumors by similarity in expression pattern. The patient dendrogram, which is based on expression profile of all 3560 cDNAs, is shown in Figure 1 . The gene expression pattern below the dendrogram (Figure 1 ) was based on 1309 genes that were significantly unique to each subtype. Two broad clusters emerged: (1) one consisting of 35 clear cell RCC and four granular RCC, and (2) all other types of kidney tumors and four clear cell RCC. In the latter group, there are different subclusters; five chromophobe RCC and two oncocytoma, seven primary and one metastatic papillary RCC, five Wilms' tumors, and three TCC. In the first main cluster of clear cell RCC, there are two subclusters: one including all patients (except one) who died of cancer ( Figure 1e ) and the other the survivors of cancer without evidence of metastasis (Figure 1d ). Two papillary RCC, one primary tumor and a metastasized lymph node, from the same patient were also examined (papillary 7P, 7 M) and were found to have very similar expression pattern, pointing to the genealogical relationship between the primary and metastatic tumor (Haddad et al., 2002) . A set of more highly expressed genes in each subtype of tumors compared to all other types of kidney tumors studied is indicated by side bars with different colors on the right-hand side of Figure 1 Six granular cell RCC did not cluster by themselves but instead were located in a 'random' fashion, indicating that they are not a single entity (Figure 1 ). The diagnoses of these six cases were made in Japan prior to the recommendation of the work group of UICC and AJCC for RCC diagnosis. The old histology slides of five of these cases were available which were re-evaluated in a blinded fashion by an expert urologic pathologist (XJY). 'Granular RCC 1, 3 and 4', which were clustered in clear cell RCC group, were reclassified as clear cell RCC. 'Granular 2', which was closely clustered with chromophobe RCC, was reassigned as a chromophobe RCC. 'Granular 5', which has a distinct histology was not clustered with any RCC group by genetic profiles. It is labeled as unclassified which may represent a novel subtype of RCC and warrant further investigation (Figure 1) .
We then used multidimensional scaling (MDS) to visualize the relationship among the profiles of all tumors. Three-dimensional (3d) visualization of the MDS data demonstrated how each RCC subtype clustered, for example, chromophobe RCC/oncocytoma, papillary RCC, Wilms' tumors and TCC (Figure 2a) . 'Granular 5', which was of aggressive type and could not be reclassified, was placed next to the sarcomatoid RCC. In addition, a large majority of clear cell RCC with poor outcome clustered to one side suggesting that they shared similar expression profiles (Figure 2b) .
We then identified differentially expressed genes which are unique in each subtype (Tables 1, 2 In the non-neoplastic renal cortex (Figure 3a ), GST-a and AMACR were present in the proximal convoluted tubules (Figure 3e , i, respectively), but absent in distal convoluted tubules, glomeruli as well as stromal cells. CAII, however, was detected in the distal convoluted tubules, but very minimal in distal tubules, glomeruli, medullary tubules and stromal cells (Figure 3m ).
Nine of 10 clear cell RCCs (90%) showed immunoreactivity to GST-a (Figure 3f ), while none of 10 papillary RCC (0%) and only one of 10 chromophobe RCCs (10%) were reactive to GST-a. All 10 papillary RCCs (100%) were strongly positive for AMACR (Figure 3k ), while one of 10 (10%) clear cell RCCs and none of 10 chromophobe RCCs were positive for AMACR. All 10 chromophobe RCC (100%) showed reactivity to CAII, while only three of 10 clear cell RCCs, one of 10 papillary RCCs and two of 10 transitional cell carcinomas of the renal pelvis showed reactivity to CAII staining. All five of five transitional cell carcinomas were positive for keratin 19, while none of 10 clear cell RCCs, one of 10 papillary RCCs and none of chromophobe RCCs were positive for keratin 19 staining. The results are summarized in Table 4 . The findings confirmed the presence of these overexpressed genes located in tumor cells not in stromal cells.
Discussion
We established that different subtypes of kidney tumors are indeed characterized by distinct molecular signatures as are many other types of cancer. These reflect the The color of each square represents the median-polished, normalized ratio of gene expression in a tumor relative to reference. Expression levels greater than the median are shaded in red, those below the median in green; black, equal to the median; and gray, inadequate or missing data. The color saturation indicates the degree of divergence from the median. The tumors clustered into two broad groups with one group consisting of primarily clear cell RCC and the other consisting of all other kidney tumors. Five chromophobe RCC and two oncocytoma are clustered close together. Each group of eight papillary RCC, five Wilms' tumors, or three TCC is clustered together. The six cases in black represent those cases that were originally diagnosed as granular cell RCC. The diagnosis after reevaluation is indicated here except case 6 (histological slide not available for re-evaluation). Case A set of the most highly expressed genes in each subtype of tumors compared to all other types of kidney tumors studied is shown by using colored side bars to the right of the image (a, chromophobe RCC; b, papillary RCC; c, Wilms' tumors; d, clear cell RCC with good outcome; e, clear cell RCC) Molecular classification of kidney tumors M Takahashi et al difference in the cell type, biology and underlying molecular mechanisms in these subtypes. This is very important especially from the point of management.
First of all, based on their distinct molecular signatures, the prognostic factors, which again can be reflected by gene expression profiles (see below), have to be determined separately in each subtype instead of by lumping all subtypes together. This most likely hold true in treatment too. The low rate of response (5-10%) for some of the trailed chemotherapy like interferon and IL-2 point to the heterogeneous nature of kidney cancers treated. It is clear that, for example, non-clearcell metastatic RCC has a high resistance to systemic therapy and poor survival (Motzer et al., 2002) . And even within the subtype such as the clear cell RCC, in the present studies there are at least two major subgroups: one group is characterized by deaths within 5 years and metastasis while the other consist of patients surviving more than 5 years without evidence of metastasis. This has further supported our previous study describing the use of expression profiles as an indicator of survival in clear cell RCC (Takahashi et al., 2001) . We also demonstrated the potential gene expression-based subclassification by studying six cases of the so-called granular cell RCC. These were old cases whose diagnoses were made prior to 1997, where the WHO classification was introduced. Although no longer supposed to be used, this diagnosis is still widely made by some pathologists. Our findings clearly support that it is not an entity. Our gene expression-based subclassification designated these cases to either chromophobe RCC or clear cell RCC. In five cases whereby old histological subtypes were available for re-evaluation, the diagnosis was in agreement with our subclassification in four of them. In one case (granular 5), it was not clustered with any subgroups and indeed re-evaluation of the slide by our expert pathologist also could not pinpoint its diagnosis. Therefore, this case may represent a novel subtype of RCC yet to be properly characterized and described. This also illustrates the potential benefits and future direction of pathology whereby the corroboration of conventional pathologist expertise/skills and expression profiling may complement each other and will be most helpful in equivocal or non-clear-cut cases.
In conjunction with this, we also used statistical method to identify potential diagnostic markers in each subtype of tumor from the expression profiles. Here, we are interested in genes that are not only differentially expressed in each subtype but also have the highest power to distinguish from one another (Tables 1, 2  and 3 ). For example, the genes that we select here for clear cell RCC are only unique to clear cell subtype and not to the other subtypes. So some of the genes that appear in our previous study on solely clear cell RCC (Takahashi et al., 2001) are not present here. Using antibodies corresponding to the four selected genes, corresponding to the antibody available, we performed immunohistochemical staining on 40 cases of primary tumors: 10 clear cell RCC, 10 papillary RCC, 10 chromophobe RCC, five oncocytoma and five transitional cell carcinoma. The results were consistent with microarray expression profiles (Table 4; Figure 3 ), confirming their potential use as novel diagnostic markers. Naturally, higher specificity and sensitivity can probably be found in other candidates that are yet to have corresponding antibodies and would require further studies to establish their use as diagnostic markers.
The functions of the majority of these genes and how they are associated with tumorigenesis in each subtype remain largely unknown. For example, the first gene on which we performed immunohistochemical staining is GST-a, which functions to protect cell by catalysing the detoxification of xenobiotics and carcinogens. Previous immunohistochemical studies have demonstrated strong expression in normal kidney, especially in the proximal tubules as well as in kidney cancer (Grignon et al., 1994) . However, its role in clear cell RCC remains unknown. The second gene studied is the AMACR gene, which plays a critical role in peroxisomal beta oxidation of branched-chain fatty acid molecules. AMACR has recently been shown overexpressed in prostate cancers at both the transcript level by microarray experiments and at the protein level (Xu et al., 2000; Luo et al., 2002; Rubin et al., 2002) . Further studies by immunohistochemistry have demonstrated the elevation of AMACR protein in more than 90% of prostate cancer cases but not in benign prostatic tissues, suggesting that AMACR may be a more specific marker than prostate-specific antigen (PSA) for prostate cancer (Jiang et al., 2001; Luo et al., 2002; Rubin et al., 2002) . This gene has never been associated with any subtype of RCC. It was 5.3 times more highly expressed in papillary RCC than in normal kidney. In addition, immunohistochemical analysis demonstrated immunoreactivity in 100% of papillary RCC cases, and in less than 10% of other subtypes of RCC (Figure 3e-h ). Obviously its role in papillary RCC remains to be elucidated and warrant further studies. The third gene we studied is CA II, which belongs to a family of zinc metalloenzymes. Our immunostaining demonstrated positivity in all chromophobe RCC (10/10) and oncocytomas (5/5). Several studies have looked at its expression in kidney as well as the phenotypes in CAII-null mice, but its role in RCC is yet to be elucidated (Brechue et al., 1991; Lai et al., 1998; Lewis et al. 1988) . Interestingly, the profiles we found for this group of tumors are similar to those previously described (Young et al., 2001) . The chromophobe RCC/oncocytomas contain abundant mitochondria and had overexpression of genes related to mitochondrial biology and oxidative phosphorylation (Table 3) , suggesting the high specificity of these genes to chromophobe RCC/oncocytomas.
TCC arising in the renal pelvis may invade the entire kidney, and as such it may be difficult to distinguish TCC from RCC. Finding new markers for TCC may facilitate its diagnosis. By immunohistochemistry, we found K19 expression in some renal tubules, benign transitional epithelium and in all five cases of TCC (Table 4) . Several genes that were highly specific for TCC which are related to skin. K19 is one of them and it has been found in the periderm, the transient superficial layer that envelops the developing epidermis (Van Muijen et al., 1987) . However, its association with TCC has never been described and further studies will be required to understand its role in RCC.
Obviously, it is beyond the scope and aims of this study to discuss all the genes we have identified in each subtype of these tumors. However, it is very obvious that more value and potential of gene expression profiling are yet to be discovered. Larger number of tumors, especially in some subtypes, with detailed clinical information will be very valuable and worthwhile for future studies. For example, it may be possible to identify the genes that can differentiate between oncocytoma, a benign tumor and chromophobe RCC. It Top 30 differential expressed cDNA in papillary RCC are listed. They are significantly more highly expressed in papillary RCC compared to all other types of kidney tumors studied by 10 000 times of permutation test. Fold change indicates papillary RCC have relatively higher expression of this fold change compared to all other types of kidney tumors studied Molecular classification of kidney tumors M Takahashi et al will also be feasible to identify the prognostic molecular signatures for other subtypes of RCC, besides clear cell RCC.
Materials and methods
Tumor samples and RNA preparation 0%  10%  0%  ND  AMACR  10%  100%  0%  0%  ND  CA II  30%  10%  100%  100%  20%  K19  0%  10%  0%  0%  100% cDNA microarray fabrication and procedures
Microarray production was performed as described (Eisen and Brown, 1999; Hegde et al., 2000) with slight modifications. Briefly, 19 968 cDNA clones were PCR amplified directly from bacterial stocks purchased from Research Genetics (Huntsville, AL, USA). Following ethanol precipitation and transfer to 384 well plates, clones were printed onto aminosilane-coated glass slides using a custom-built robotic microarrayer. Slides were chemically blocked using succinic anhydrate after UV light crosslinking. When available, cancers were hybridized against patient-matched noncancerous kidney tissue. For tumors without their matched noncancerous kidney tissue available, RNA from five noncancerous kidney tissues was mixed and pooled to serve as a common reference. For the first 45 samples, 2 mg of poly(A) þ RNA from tumors and reference were reverse transcribed with oligo (dT) primer and Superscript II (Invitrogen, Carlsbad, CA, USA) in the presence of Cy5-dCTP and Cy3-dCTP (Amersham Pharmacia Biotech, Peapack, NJ, USA). For the remaining 25 samples, 50 mg of total RNA from tumors and reference were used for reverse transcription. The Cy5-and Cy3-labeled cDNA probes were mixed with probe hybridization solution containing formamide and hybridized to prewarmed (501C) slides for 20 h at 501C. Following hybridization, slides were washed in 1 Â SSC, 0.1% SDS at 501C for 5 min followed by 0.2 Â SSC, 0.1% SDS at room temperature (RT) for 5 min, 0.2 Â SSC at RT for 5 min twice and 0.1 Â SSC at RT for 5 min. Slides were dried immediately by centrifugation and scanned using a Scan Array Lite scanner at 532 and 635 nm wavelengths (GSI Lumonics, Billerica, MA, USA).
Data analysis
Images were analysed using the software Genepix Pro 3.0.
(Axon, Union City, CA, USA). The local background was subtracted for all spots. Spots whose background-subtracted intensities in either Cy5 or Cy3 channel were less than 150 were excluded from the analysis. The ratio of Cy5 intensity to Cy3 intensity was calculated for each spot, representing tumor RNA expression relative to noncancerous kidney tissue. Ratios were log transformed (base 2) and normalized so that the median log-transformed ratio equaled zero. Genes with the following criteria (3560 genes in total) were selected for the global clustering analysis: (1) expression values present in at least 70% of the tumors; (2) expression ratios that varied at least twofold in at least two tumors; and (3) maximum ratio minus minimum ratio values greater than twofold. The gene expression ratios were median polished across all samples.
Gene expression values were manipulated and visualized using the CLUSTER and TREEVIEW software (M.B. Eisen, http:// rana.lbl.gov). The correlation distances were calculated as 1Àr, where r indicates the Pearson correlation coefficient (Eisen et al., 1998) . The in-house software program, CIT, was used to find genes that were differentially expressed (using a Student's t-test) between one histological subtype and the others (Rhodes et al., 2002) . To find significant discriminating genes, 10 000 tstatistics were calculated by randomly placing patients into two groups (Hedenfalk et al., 2001) . A 99.9% significance threshold (ap0.01) was used to identify genes that could significantly distinguish between two patient groups versus the random patient groupings.
Immunohistochemistry
A total of 50 cases of benign (N ¼ 10) and neoplastic renal tissues (N ¼ 40) were analysed using immunohistochemistry. Kidney tumors included clear cell RCC (N ¼ 10), papillary RCC (N ¼ 10), chromophobe RCC (N ¼ 10), oncocytoma (N ¼ 5) and TCC (N ¼ 5). A section from each kidney tissue was stained for H&E to verify histology. The following antibodies were obtained commercially: GST-a (Dako, Carpinteria, CA, USA), a methylacyl racemase (Corixa, Seattle, WA, USA), CAII (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and keratin 19 (Dako, Carpinteria, CA, USA). Standard biotin-avidin complex immunohistochemistry was performed. Briefly, tissue sections were then incubated with primary antibodies for 30 min at 201C. Then, the slides were incubated with biotinylated anti-mouse IgG or anti-rabbit IgG (Vector Laboratories, Burlingame, CA, USA) at 271C for 30 min and the antigen-antibody complexes were detected with avidin-biotinylated horseradish peroxidase system (Vector, Burlingame, CA, USA) using DAB as a chromogen and hematoxylin as a counterstain. The slides were evaluated as either negative or positive by an expert urologic pathologist (XJY).
